FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Vashington,	D.C. 20549
-------------	------------

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL											
OMB Number:	3235-0287										
Estimated average burden											
hours per response:	0.5										

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* SIEBERT JOHN M						2. Issuer Name and Ticker or Trading Symbol SUPERNUS PHARMACEUTICALS, INC.										Relationship of Reporting Person(s) to Issuer (Check all applicable)     X Director 10% Owner					
					[ <mark>S</mark>	UPN	]								-	X Directo					
(Last)	(Last) (First) (Middle) C/O SUPERNUS PHARMACEUTICALS, INC.,					oate of 23/20		est Tran	sac	tion (Mo	nth/E	Day/Year)			Officer (give title below)		Other (s below)	pecify			
9715 KEY WEST AVENUE					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)									Line	6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street)	ILLE N	MD .	20850														iled by Mor		orting Persor		
(City) (State) (Zip)					Ru	Rule 10b5-1(c) Transaction Indication  Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to															
						satisf	y the a	ox to inc	e def	e that a tr fense con	ansa ditior	otion was r	nade 10b5-	nursuani 1(c). See	Instruction	on 10.	on or written	pian ti	nat is intende	ı to	
		Tab	le I - Nor	n-Deriv	ative	Sec	uriti	ies Ac	qu	ıired, [	Disp	osed o	of, o	r Ben	eficial	ly Owne	t				
1. Title of Security (Instr. 3)  2. Transport Date (Month/L					extion 2A. Deer Execution (ay/Year) 15 any (Month/E						Dispose	curities Acquired (A) osed Of (D) (Instr. 3, 4			Benefici	es For ially (D) Following (I) (		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership Instr. 4)		
										Code	v	Amount	(A) or (D)		Price	Transac (Instr. 3	tion(s)			(111341. 4)	
Common Stock 02/23/				3/2024					A		3,88	6	A	\$0	87,943			D			
		T	able II - I									sed of onverti				Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day	Date,		ransaction ode (Instr.		of		6. Date Exercisable Expiration Date (Month/Day/Year)			nd 7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ve es ally ng d tion(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Da Ex	ite ercisable		xpiration ate	Title	1	Amount or lumber of Shares						
Restricted Stock Unit	(1)	02/23/2024			D			3,886		(2)		(2)		nmon	3,886	\$0	0		D		

## **Explanation of Responses:**

- 1. Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
- 2. These restricted stock units are settled in common stock upon vesting, which occurred on February 23, 2024.

/s/ Timothy C. Dec, as 02/27/2024 attorney-in-fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.